159 related articles for article (PubMed ID: 34625505)
21. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.
Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y
Front Immunol; 2022; 13():863346. PubMed ID: 35874730
[TBL] [Abstract][Full Text] [Related]
22. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.
Li Q; Qin S; Tian H; Liu R; Qiao L; Liu S; Li B; Yang M; Shi J; Nice EC; Li J; Lang T; Huang C
Small; 2023 Jun; 19(23):e2207201. PubMed ID: 36899444
[TBL] [Abstract][Full Text] [Related]
23. Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer.
Li E; Xu J; Chen Q; Zhang X; Xu X; Liang T
Immunotherapy; 2023 Feb; 15(3):135-147. PubMed ID: 36779368
[TBL] [Abstract][Full Text] [Related]
24. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
Pan CH; Otsuka Y; Sridharan B; Woo M; Leiton CV; Babu S; Torrente Gonçalves M; Kawalerski RR; K Bai JD; Chang DK; Biankin AV; Scampavia L; Spicer T; Escobar-Hoyos LF; Shroyer KR
Mol Oncol; 2020 Aug; 14(8):1800-1816. PubMed ID: 32533886
[TBL] [Abstract][Full Text] [Related]
25. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.
Henry KE; Mack KN; Nagle VL; Cornejo M; Michel AO; Fox IL; Davydova M; Dilling TR; Pillarsetty N; Lewis JS
Mol Cancer Ther; 2021 Oct; 20(10):2026-2034. PubMed ID: 34349003
[TBL] [Abstract][Full Text] [Related]
26. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.
Ye J; Gavras NW; Keeley DC; Hughson AL; Hannon G; Vrooman TG; Lesch ML; Johnston CJ; Lord EM; Belt BA; Linehan DC; Eyles J; Gerber SA
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142292
[TBL] [Abstract][Full Text] [Related]
27. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma.
Kong Y; Xie F; Zhang Z; Wang S; Zhang Y; Di Y; Zhou Z; Jiang D; Li J; Huang Q; Wang J; Li X; Pan Z; Ni R; Guan Y
Eur Radiol; 2023 Oct; 33(10):7077-7088. PubMed ID: 37166496
[TBL] [Abstract][Full Text] [Related]
29. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
[TBL] [Abstract][Full Text] [Related]
30. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
Panchal K; Sahoo RK; Gupta U; Chaurasiya A
Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
[TBL] [Abstract][Full Text] [Related]
31. TGF-β Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma.
Trebska-McGowan K; Chaib M; Alvarez MA; Kansal R; Pingili AK; Shibata D; Makowski L; Glazer ES
J Gastrointest Surg; 2022 Jan; 26(1):113-121. PubMed ID: 34260016
[TBL] [Abstract][Full Text] [Related]
32. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
33. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
34. CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer.
Piro G; Carbone C; Agostini A; Esposito A; De Pizzol M; Novelli R; Allegretti M; Aramini A; Caggiano A; Granitto A; De Sanctis F; Ugel S; Corbo V; Martini M; Lawlor RT; Scarpa A; Tortora G
Br J Cancer; 2023 Jan; 128(2):331-341. PubMed ID: 36385556
[TBL] [Abstract][Full Text] [Related]
35. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
[TBL] [Abstract][Full Text] [Related]
36. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
[TBL] [Abstract][Full Text] [Related]
37. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
[TBL] [Abstract][Full Text] [Related]
38. A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.
Bassani-Sternberg M; Digklia A; Huber F; Wagner D; Sempoux C; Stevenson BJ; Thierry AC; Michaux J; Pak H; Racle J; Boudousquie C; Balint K; Coukos G; Gfeller D; Martin Lluesma S; Harari A; Demartines N; Kandalaft LE
Front Immunol; 2019; 10():1832. PubMed ID: 31440238
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy.
Azad A; Yin Lim S; D'Costa Z; Jones K; Diana A; Sansom OJ; Kruger P; Liu S; McKenna WG; Dushek O; Muschel RJ; Fokas E
EMBO Mol Med; 2017 Feb; 9(2):167-180. PubMed ID: 27932443
[TBL] [Abstract][Full Text] [Related]
40. Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma.
Rohila D; Park IH; Pham TV; Weitz J; Hurtado de Mendoza T; Madheswaran S; Ishfaq M; Beaman C; Tapia E; Sun S; Patel J; Tamayo P; Lowy AM; Joshi S
Cancer Res; 2023 Aug; 83(16):2675-2689. PubMed ID: 37306759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
